MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$219,058K
Net Income
-$58,371K
Net Profit Margin
-26.65%
EPS
-$1.01
Unit: Thousand (K) dollars
Revenue Breakdown
Qelbree
GOCOVRI
Collaboration Revenue
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues
219,058
207,705
211,572
192,103
Cost of revenues
33,669
23,391
23,007
18,965
Research and development
29,463
39,438
27,827
29,366
Selling, general and administrative
133,637
125,173
122,390
179,678
Amortization of intangible assets
25,333
25,644
24,526
24,325
Intangible asset impairment charges
54,919
-
0
-
Contingent consideration loss
0
2,391
17,759
0
Total costs and expenses
277,021
216,037
215,509
252,334
Operating earnings (loss)
-57,963
-8,332
-3,937
-60,231
Interest and other income, net
2,630
2,382
2,023*
2,277
Interest expense
2,315
-
0*
-
Total other income, net
315
2,382
2,023
2,277
Earnings (loss) before income taxes
-57,648
-5,950
-1,914
-57,954
Income tax expense (benefit)
723
-3,657
2,191
-12,837
Net earnings (loss)
-58,371
-2,293
-4,105
-45,117
Basic EPS
-1.01
-0.04
-0.072
-0.8
Diluted EPS
-1.01
-0.04
-0.072
-0.8
Basic Average Shares
58,070,378
57,647,548
57,362,340
56,552,741
Diluted Average Shares
58,070,378
57,647,548
56,743,922
56,552,741
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net earnings (loss)
-$58,371K
(-359.44%↓ Y/Y)
Interest and other
income, net
$2,630K
(-41.92%↓ Y/Y)
Qelbree
$89,239K
(15.08%↑ Y/Y)
GOCOVRI
$37,530K
(2.37%↑ Y/Y)
ONAPGO
$13,546K
(744.51%↑ Y/Y)
Oxtellar XR
$8,782K
(-24.53%↓ Y/Y)
Trokendi Xr
$8,411K
(-24.85%↓ Y/Y)
APOKYN
$6,323K
(-50.68%↓ Y/Y)
Manufactured Product Other
$1,882K
(-71.20%↓ Y/Y)
Earnings (loss) before
income taxes
-$57,648K
(-445.84%↓ Y/Y)
Income tax expense
(benefit)
$723K
(112.40%↑ Y/Y)
Total other income,
net
$315K
(-93.04%↓ Y/Y)
Product
$165,713K
(4.88%↑ Y/Y)
Collaboration Revenue
$35,350K
Royalty License And
Other Revenue
$17,995K
(141.28%↑ Y/Y)
Interest expense
$2,315K
Operating earnings (loss)
-$57,963K
(-577.42%↓ Y/Y)
Total revenues
$219,058K
(32.40%↑ Y/Y)
Total costs and
expenses
$277,021K
(80.69%↑ Y/Y)
Selling, general and
administrative
$133,637K
(42.85%↑ Y/Y)
Intangible asset
impairment charges
$54,919K
Cost of revenues
$33,669K
(100.09%↑ Y/Y)
Research and development
$29,463K
(33.23%↑ Y/Y)
Amortization of intangible
assets
$25,333K
(21.68%↑ Y/Y)
Buy us a coffee
SUPERNUS PHARMACEUTICALS, INC. (SUPN)
SUPERNUS PHARMACEUTICALS, INC. (SUPN)